U.S. Neurology Clinical Trials Market Size Worth USD 6.07 Billion by 2034 | CAGR: 6.7%

The U.S. neurology clinical trials market size is expected to reach USD 6.07 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. neurology clinical trials market involves the research and development of new drugs, therapies, and medical devices designed to treat conditions of the nervous system. This includes a wide range of diseases and disorders affecting the brain, spinal cord, and peripheral nerves, such as Alzheimer's, Parkinson's, epilepsy, and stroke.

The U.S. biotechnology and pharmaceutical industry is at the forefront of neurology innovation, driving the development of next-generation therapies. Many companies are investing heavily in neurological research, focusing on disease-modifying treatments and gene therapies. Startups and established firms alike are targeting unmet needs in Alzheimer’s, ALS, and rare neurogenetic disorders. These innovations require rigorous clinical testing, leading to an increase in U.S.-based neurology trials. The country’s strong investment climate and venture capital ecosystem further support R&D in this field, pushing more candidates into the clinical pipeline.

Have Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-neurology-clinical-trials-market/request-for-sample

Public awareness of neurological disorders in the U.S. is growing, due to education campaigns and active advocacy from organizations such as the Alzheimer’s Association, Parkinson’s Foundation, and Epilepsy Foundation. These groups help educate patients and caregivers about available clinical trials and often partner with research institutions to boost participation. Consequently, patient enrollment has improved significantly in recent years. High public engagement also drives demand for faster innovation and motivates stakeholders to invest in clinical research, further propelling the growth of neurology trials across the U.S.

U.S. Neurology Clinical Trials Market Report Highlights

• The phase III segment dominated the market in 2024, supported by a strong emphasis on validating the safety and efficacy of neurological treatments in large patient populations.
• The observational studies segment is expected to witness the fastest growth during the forecast period, fueled by the rising need for real-world data to better understand long-term outcomes in neurology research.
• A few key players in the market include IQVIA, ICON plc, Syneos Health, Laboratory Corporation of America Holdings, Charles River Laboratories, Thermo Fisher Scientific, Parexel, Medpace Holdings, and pharmaceutical companies like Pfizer, Biogen, and Eisai Co.

Polaris Market Research has segmented the U.S. neurology clinical trials market report based on phase, study design, indication, and value chain:

By Phase Outlook (Revenue – USD Billion, 2020–2034)

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design Outlook (Revenue – USD Billion, 2020–2034)

• Interventional
• Observational
• Expanded Access

By Indication Outlook (Revenue – USD Billion, 2020–2034)

• Alzheimer’s Disease
• Depression (MDD)
• Parkinson's Disease (PD)
• Epilepsy
• Stroke
• Traumatic Brain Injury (TBI)
• Amyotrophic Lateral Sclerosis (ALS)
• Huntington's Disease
• Muscle Regeneration
• Others

By Value Chain Outlook (Revenue – USD Billion, 2020–2034)

• In-house
• CROs
• Investigator Sites/Clinical Sites